AcclaimIP-ad

Match Document Document Title
10022435 Nucleic acid vaccines  
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more...
US20180196061 INFLUENZA POTENCY ASSAYS  
The present application discloses stability-indicating potency assays for influenza vaccines.
10016495 Oil-in-water emulsion influenza vaccine  
The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant...
US20180186897 NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA  
The present invention provides a pharmaceutical composition, for example a vaccine, which comprises a RIFIN, which is able to bind to a mutated LAIR-1 fragment, which broadly binds to erythrocytes...
US20180186896 VACCINES FOR THE TREATMENT AND PREVENTION OF IGE MEDIATED DISEASES  
Disclosed is a vaccine for use in the prevention or treatment of an Immunoglobulin E (IgE-) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said...
US20180177871 ADJUVANTED FORMULATIONS OF BOOSTER VACCINES  
The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is...
US20180177862 ANTIGENICALLY MATCHED INFLUENZA VACCINES  
Disclosed herein are influenza vaccine compositions, related preparations and intermediates, formulations, production methods, immunization methods, and use thereof, for achieving improved...
RE46906 Methods for producing vaccine adjuvants  
An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to...
US20180171337 THERAPEUTIC OLIGONUCLEOTIDES  
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The...
US20180169227 IMMUNITY INDUCTION PROMOTING COMPOSITION, AND VACCINE PHARMACEUTICAL COMPOSITION  
The present invention provides an immunity induction-promoting composition which has a track record of use as a medicine or medicinal additive and is capable of safely and effectively inducing...
US20180169225 METHODS FOR PREPARING SQUALENE  
An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T1 (b) a...
US20180169219 HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF  
The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2...
US20180169204 COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT  
Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have...
US20180169202 COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY  
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one...
US20180169201 COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY  
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one...
US20180162913 METHODS FOR POTENTIATING AN IMMUNE RESPONSE USING DEPOT-FORMING AND NON-DEPOT-FORMING VACCINES  
The present disclosure provides methods, vaccines and kits for potentiating an immune response to an antigen in a subject. The methods comprise administering to the subject at least one dose of a...
US20180161412 EXTENDED PROTECTION PROTEIN VACCINES AGAINST INFECTIOUS AGENTS  
Protein-based vaccines against infectious agents, including malaria and Zika virus, are described. The protein-based vaccines include an antigen domain and an immature dendritic cell targeting...
9994630 Clostridium difficile antibodies  
Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The...
9994443 Modified nicotinic compounds and related methods  
Provided herein are compounds and related composition and methods that may be used to raise an antibody response to nicotinic compounds, in some embodiments.
US20180153983 CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIDES  
The invention provides a process for preparing a conjugate of a S.aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular...
9987345 OMV vaccines  
The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant...
9987344 Pseudomonas antigens and antigen combinations  
An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunization. These polypeptides may...
9987341 PCSK9 vaccine  
The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of...
US20180148727 ARTIFICIAL NUCLEIC ACID MOLECULES  
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR element) and/or at least one...
US20180147269 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE  
Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides...
9981031 Injectable vaccines against multiple meningococcal serogroups  
An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated...
9981030 Glycan conjugates and use thereof  
Described herein are synthetic glycan conjugates comprising a carrier and a glycan moiety derived from Neisseria meningitidis, wherein the glycan moiety is covalently linked to the carrier through...
9981029 Multivalent pneumococcal polysaccharide-protein conjugate composition  
Provided is an immunogenic composition comprising 13 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from a different serotype...
9974855 Humanized anti-CD40 antibodies and methods of administering thereof  
The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies...
9974845 Combination of vaccination and inhibition of the PD-1 pathway  
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one...
US20180134799 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF  
The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical...
9968670 Influenza virus vaccines and uses thereof  
Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
US20180125958 Immunogenic Compositions and Uses Thereof  
The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a...
US20180125952 PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT  
The present invention relates to prime-boost regimens that involve the administration of at least one mRNA construct, such as the use of such constructs in “boost” administration subsequently to...
9956289 Emulsion compositions containing quaternary ammonium compounds  
Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in...
US20180110846 IL-23-P19 VACCINES  
Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein...
9950062 Compounds and compositions as TLR activity modulators  
The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent...
9950051 Formulations  
This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material...
US20180104324 IMMUNOGENIC COMPOSITION  
Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to...
9945864 Disease-associated antigens and methods of use thereof  
The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides...
9943588 Influenza vaccine  
The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in...
US20180099039 Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof  
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic...
US20180092970 CHLAMYDIA ANTIGENS  
The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279,...
9931399 Adjuvanted formulations of booster vaccines  
The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is...
9931393 Immunogenic JC polyomavirus compositions and methods of use  
Methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid...
US20180085388 DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS  
RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the...
9926344 Stabilised proteins for immunising against Staphylococcus aureus  
Elimination of disulphide bond formation of cysteine-containing S. aureus antigens enhances antigen stability. The invention provides variant forms of cysteine-containing S. aureus antigen with a...
9926343 Mutant fragments of OspA and methods and uses relating thereto  
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use...
US20180078640 HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF  
The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies...
US20180078629 COMBINATION OF VACCINATION AND INHIBITION OF MHC CLASS I RESTRICTED ANTIGEN PRESENTATION  
The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex...
« search again